TABLE 4.

Primary and Secondary Outcomes With Canagliflozin 300 mg (n = 4)

Baseline Mean (SD)First Follow-Up Mean (SD)Difference: Baseline to First Follow-UpPSecond Follow-Up Mean (SD)Difference: Baseline to Second Follow-UpP
A1C, %8.70 (1.04)7.90 (0.88)–0.800.096*7.93 (1.04)–0.780.031**
BMI, kg/m233.08 (5.37)31.76 (6.11)–1.310.056*31.72 (6.21)–1.360.103
Weight, kg103.90 (20.68)99.83 (22.80)–4.080.054*99.80 (23.70)–4.100.094*
SBP, mmHg123.00 (11.94)119.50 (6.81)–3.500.667120.00 (15.58)–3.000.406
DBP, mmHg83.00 (15.45)70.50 (9.98)–12.500.18872.50 (10.38)–10.500.354
  • * Significant at α = 0.10.

  • ** Significant at α = 0.05.